The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.

Could AstraZeneca's Asthma Drug Candidate Generate Billions?

09:30am, Tuesday, 20'th Dec 2022

AstraZeneca's new asthma rescue treatment could soon be approved in the United States for adults.

AstraZeneca posts mixed results from lung cancer trial

04:16am, Monday, 19'th Dec 2022

AstraZeneca shares slipped as it reported mixed results from its latest trial (PEARL) of the cancer drug Imfinzi. Using Imfinzi as a single therapy for lung cancer sufferers, the drug missed its prima

AstraZeneca's Forxiga gets EU approval recommendation for symptomatic chronic heart failure

03:27am, Monday, 19'th Dec 2022

AstraZeneca PLC said Monday that its Forxiga drug has been recommended for approval in the European Union for certain types of heart failure.

AstraZeneca's Imfinzi plus Imjudo recommended for approval in the EU

02:54am, Monday, 19'th Dec 2022

By Anthony O. Goriainoff

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

12:48pm, Friday, 16'th Dec 2022

The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.

AstraZeneca's new drug application for Lynparza given more time by US FDA

03:11am, Thursday, 15'th Dec 2022

AstraZeneca PLC (LSE:AZN), and its US peer Merck & Co, announced that the US Food and Drug Administration (FDA) will allow more time to review the new drug application for its cancer drug, Lynparza. T

Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?

11:17am, Wednesday, 14'th Dec 2022

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

4 Large Drug Stocks to Watch in a Booming Industry

09:47am, Wednesday, 14'th Dec 2022

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca

AstraZeneca attractive in near term but patent cliffs loom, says broker

08:12am, Wednesday, 14'th Dec 2022

AstraZeneca has a “positive catalyst path ahead” in the near term given its oncology project pipelines, according to broker Jefferies, but earnings forecasts were lowered. A ‘hold' rating was fo

AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy Zone

03:19pm, Tuesday, 13'th Dec 2022

AstraZeneca is breaking out on the strength of its relative strength highs and as profits continue to grow. The post AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy Zone appeared first

AstraZeneca a ‘buy' for project pipeline potential – broker

11:32am, Friday, 09'th Dec 2022

Shore Capital has reiterated its ‘buy' stance on pharma giant AstraZeneca following data on its late-stage breast cancer drugs presented at a San Antonio conference, AstraZeneca's projects have “t

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by